{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:30Z","timestamp":1786951470040,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jdcr.2026.06.019","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:49:53Z","timestamp":1781506193000},"page":"218-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Repurposing therapies in junctional epidermolysis bullosa: Oral ivermectin therapy associated with improved wound healing and reduced pruritus"],"prefix":"10.1016","volume":"74","author":[{"given":"Brandon","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"D\u00e9d\u00e9e F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2026.06.019_bib1","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/jdv.16859","article-title":"Splicing of the cake can affect the severity of epidermolysis bullosa","volume":"34","author":"Murrell","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.06.019_bib2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jid.2018.10.017","article-title":"Phenotypic spectrum of epidermolysis bullosa: the paradigm of syndromic versus non-syndromic skin fragility disorders","volume":"139","author":"Vahidnezhad","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.06.019_bib3","article-title":"Ivermectin: a multifaceted drug with a potential beyond anti-parasitic therapy","volume":"16","author":"Kaur","year":"2024","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.jdcr.2026.06.019_bib4","first-page":"353","article-title":"Scabbia norvegese ed epidermolisi bollosa distrofica recessiva: efficacia della terapia con ivermectina [Successful treatment of Norwegian scabies with ivermectin in a patient with recessive dystrophic epidermolysis bullosa]","volume":"56","author":"Angelo","year":"2004","journal-title":"Minerva Pediatr"},{"issue":"1","key":"10.1016\/j.jdcr.2026.06.019_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.2000.03281.x","article-title":"Crusted scabies in a girl with epidermolysis bullosa simplex","volume":"142","author":"Torrelo","year":"2000","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.06.019_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/1203475419867611","article-title":"The role of IL-17 in papulopustular rosacea and future directions","volume":"23","author":"Amir Ali","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jdcr.2026.06.019_bib7","first-page":"317","article-title":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"8","key":"10.1016\/j.jdcr.2026.06.019_bib8","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1111\/jdv.19859","article-title":"Phenotypic differences in intermediate generalized junctional epidermolysis bullosa with homozygous LAMC2 mutation and a potential genetic modifier","volume":"38","author":"Cowan","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jdcr.2026.06.019_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s13555-021-00561-5","article-title":"Clinical perspectives of gene-targeted therapies for epidermolysis bullosa","volume":"11","author":"Welponer","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.jdcr.2026.06.019_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13555-017-0176-3","article-title":"Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models","volume":"7","author":"Thibaut de M\u00e9nonville","year":"2017","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626003668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626003668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:36:49Z","timestamp":1786948609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626003668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"alternative-id":["S2352512626003668"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.06.019","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing therapies in junctional epidermolysis bullosa: Oral ivermectin therapy associated with improved wound healing and reduced pruritus","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}